isms causing enteritis and enterocolitis in humans [1] . Furthermore, extraintestina1 manifestations-including skin lesions and chronic persistent infections-may occur, particularly in immunocompromised individuals (such as patients with severe hypogammaglobulinemia) [1] [2] [3] [4] [5] [6] . Moreover, C. jejuni infections have been linked to immunopathologic sequelae, including reactive arthritis and Guillain-Barre syndrome [1] .
Treatment with antibiotics such as erythromycin, imipenem, and ciprofloxacin is recommended in severe cases (e.g., cases in immunocompromised patients) [1, 2] . However, a significant number (5%-50%) of C. jejuni isolates have been demonstrated to be resistant to several antibiotics, including quinolones [I, 7, 8] . Hence, additional immunomodulating therapy including intravenous and/or oral Ig preparations has been used in the treatment of C.jejuni infections in immunocompromised patients and has proved to be efficient [2, 9, 10] .
In agreement with clinical data, recent work from our laboratory demonstrated that IgM antibodies may enhance the bactericidal effects of polymorphonuclear leukocytes (PMNLs) against C.jejuni [10] . However, because of the lack of appropriate animal models for C. jejuni infections, there are practically no systematic data available on the immunobiology of C. jejuni infections.
Herein, we report a case ofrefractory systemic infection with an unusual hippurate-negative C. jejuni strain that occurred in a patient with X-linked agammaglobulinemia (XLA); conventional therapy with antibiotics and Igs failed to cure the infection.
Case Report and Laboratory Investigations
A baby boy was born as the third child of healthy parents. At 6 months of age, severe hypogammaglobulinemia was diagnosed; the count of circulating B cells was very low, but the counts and functions of T cells were normal. Since his older brother also had extremely low serum levels of Ig as well as no circulating B cells, XLA was diagnosed and confirmed by indirect DNA methods (including restriction fragment length polymorphism analysis). The boy received regular intravenous infusions of Ig (Endobulin containing pooled human Igs [99.9%, IgG; 0.1%, IgA], Immuno, Heidelberg, Germany) at a dose of 400 mg/kg of body weight every 4 weeks and was doing well except for repeated episodes of otitis media.
At the age of 7 years, the boy was admitted to the Children's Hospital of Wiirzburg Medical School (Wiirzburg, Germany) because of a 4-month history of a generalized pruritic rash. Physical examination revealed numerous grouped and disseminated maculopapular skin lesions with small vesicles or crusts on the summit (figure 1). There was extensive excoriation. The lesions were most pronounced on the trunk and on the extensor surfaces ofthe extremities. There were no other abnormal physical findings. The patient was afebrile and had no history of fever or chills during the preceding months.
Laboratory investigations revealed an erythrocyte sedimentation rate of 4 mm/h and a WBC count of 12.6 X 10 9/L (57% neutrophils, 25% lymphocytes, 11% monocytes, 4% band forms, 2% eosinophils, and 1% basophils). Three weeks after the last dose of Endobulin, the serum concentration of IgG was 475 mg/dL. IgA, IgM, and IgE levels were undetectable. Total complement activity (CH50, AP50) was normal. After admission, routine procedures were used to isolate C. jejuni several times from blood and stool specimens from the patient; cultures of the samples on plates of meat-yeast extract agar were incubated for 48 hours at 42°C under microaerobic conditions (Anaerocult C, Merck, Darmstadt, Germany). The strain did not hydrolyze hippurate but was identified as C.jejuni by determination of ]6S rRN A gene sequences according to the method of Giesendorf et al.
[II] and as C. jejuni serotype Lior II by slide agglutination according to the method of Lior et al. [12] . A region of the 16S RNA gene was amplified by PCR analysis with the Campylobacterspecific primer pair C422 and C490, which correspond to Escherichia coli positions 399-420 and 825-803, respectively [12] . The resulting PCR fragment (426 bp) was sequenced by the Taq-cyc1e Dye Deoxy terminator method [13] in combination with a 373A automatic sequencer (Perkin Elmer, Weiterstadt, Germany) . Database searches revealed 100% sequence homology with C. jejuni. The presence of polymerase inhibitory substances and the specificity were controlled with the use of human ,B-actin-specific primers [13] , which amplified a fragment of 348 bp.
The C. jejuni strains repeatedly isolated from the patient before and after antimicrobial therapy appeared to be identical (determined by the above-mentioned methods) and exhibited an identical pattern of antimicrobial susceptibility, thus suggesting chronic persistent infection rather than reinfection with other strains of C. jejuni. The strains were susceptible to gentamicin (10 The boy was initially treated intravenously with amoxicillin (500 mg three times a day for ]4 days) and doxycycline (200 mg/d for 10 days) and then with imipenem (500 mg twice a day for 10 days). He also received bovine colostrum (10 g orally twice a day for ]0 days; Lactobin, Biotest Pharma, Dreieich, Germany). Moreover. Endobulin was substituted by an intravenous Iglvl-containing preparation (Pentaglobin, Biotest Pharma). Although blood cultures became sterile , serial stool cultures , spanning nearly 18 months , demonstrated persistent excretion of C.jejuni. Furthermore, there was no beneficial effect of treatment on skin manife station s, which appeared to be intractable.
Several months later, skin biopsy specimens were taken to elucidate the etiology of the skin alterations. Although skin aspirates and biopsy specimens were sterile, PCR techniques revealed the presence of C. jejuni DNA in the skin lesions , thereby suggesting that the skin lesions were due to C. jejuni infection (figure 2). Cultures of parallel blood specimens taken at this time were negative . Therefore, on the basis of the results obtained by the in vitro studies (which are discussed below) and with the informed consent of both parents, the decision was made to treat the boy with maternal plasma (10 mL/[kg of body weight· w] for 5 weeks) in combination with ciprofloxacin (250 mg orally twice a day for 3 weeks). Stool culture s became negative 5 days after the start of treatment, and the skin lesions completely resolved within 6 weeks (figure I) . During a 12-month follow-up period, stool cultures remained negative , and the patient continues to be asymptomatic.
Experimental Procedures

Prolif erative responses of peripheral blood mononuclear cells (PBMCs).
PBMCs were isolated by Ficoll (Biochrom, Berlin) density gradient centrifugation. PBMCs (105) were inoculated in triplicate into wells on 96-well microtiter plates that contained RPMI 1640 tissue culture medium (Biochrom, Berlin) supplemented with 10% AB serum (Sigma, Deisenhofen, Germany) and horse serum (Gibco BRL, Eggen stein, Germany). The cells were stimulated with 10 JLg of a heat-killed preparation of C. jejuni, Listeria monocyt ogenes, Yersinia enterocolitica, or Salmonella typhimurium per milliliter or with 100 JLg of tetanu s toxoid per milliliter. Six days later, 0.5 JLCi of eH]thymidine was added to each well. After a further 6 hours of incubation, cells were harvested, and eH]thymidine uptake was determined.
PMNL functions. Blood was taken from the patient, his mother , and unrelated healthy controls (laboratory personnel). PMNLs were prepared as recently described [14] . Luminol (Sigma)-amplified chemiluminescence (CL) of PMNLs was performed, and the PMNL responses were measured by a microplate chemiluminometer (Hamamatsu Photonics, HCITsching, Germany) at 37°C as described previously [14] . Briefly, 105 PMNL s per well were incubated with RPMI 1640 cell culture medium containing 2.5 X 10-5 M luminol. For stimulation, viable C. jejuni (10-100 bacteria per PMNL) or 10 JLg of heat-killed C.jejuni or zymosan (Sigma, Munich) was added to various Ig preparations or sera. Light emission was recorded continuously for 90 minut es. The total light emission was calculated as previously described [14] . Three separate experiments with triplicate wells revealed comparable results.
Modulation of the bactericidal act ivity of PMNLs against C. jej uni was shown by the above-described microplate assay with various Ig preparations and sera . PMNLs were incubated with C. jejuni at a ratio of I: I00 for 30 minutes at 37°e. Subsequently, 30 JLg of gentamicin/mL was added to kill extracellular bacteria. Two hours later, cells were washed and lysed with PBS containing 0.5% bovine serum albumin and 0.5% Tergitol (Fluka, Buchs, Switzerland). were exposed to C. jej uni in serum derived from the patien t' s health y mother (P < .05; figure 3 ). Likewise, comparable results were obtained when the mother' s PMNL s (P < .05) or PMNLs from unrelated health y control s (data not shown) were used (figure 3), thus suggesting that certain components of the patient ' s serum that are required for triggering C. jeju nispecific CL respo nses by PMNLs were lacking. In addition, stimulation with zymosan, which is opsonized by complement C3b, caused compara ble CL responses by PMNLs from the patient and his mother (figure 3), thereby suggesting that C. j ejlllli -specific compounds (such as antibodies ) were lacking in the patient's serum .
Since it has not yet been establi shed that reactive oxygen metabolites mediate the killing of C. jeju ni, the bactericidal activity of PMNL s was directly determined. For this purpo se, PMNLs were mixed with viable C. jej uni in various sera and 19 compounds, and a gentamicin assay was perform ed. The results (figure 4) showed that the CL respons es of PMNL s that are depicted in figure 3 correlated directly with bacterial killing by PMNL s. Thus , apart from Pentaglobin, which significantl y enhanced the bactericidal effects of PMNLs against C. jejuni (P < .05), the commercial Ig preparat ions had no effec t and even reduced killing. However, as observed for CL respons es. addition of mate mal serum to the patient' s PMNLs most vigorously enhan ced the bactericidal activity against Campylobacter (P < .05).
On the basis of these resu lts, the decision was made to transfuse matemal plasma to enhance the patien t's defe nse again st C. j ejuni infection. Since the patient's clini cal condition A hippurate-negative C.jejuni strain caused a chronic refractory infection in a patient with XLA ; this infection persi sted despite treatment with different antibiotics (amoxicillin, doxycycline, and imipenem) and intravenously and orally administered Ig preparations (Endobulin, Pentaglobin, and Lactobin).
This trea tmen t caused clearance of C. j ejuni from the blood but not from the intestine and skin lesions .
The rationale for new treatment with matemal plasma and ciprofloxacin for this patient was based on the findings of PCR analysis, which revealed that C.j ejuni may pers ist not only in the intestine (or the blood) but also in tissue (e.g., skin) lesions.
Moreover, the possibility that C. jej uni may persist intracellularly cannot be excluded, and thus , this persi stence may evade substitution therapy with Ig or certain antibiotics (such as gentamicin) that only act extracellularly. Therefore, we believed that combination therapy with antibiotics that act both intrace llularly and extracellularly and immunomodulating compounds that act rather extracellularly should mediate a rapid clearance of the bacteria from both the blood and the gut; on the other hand , we thought that this combination therapy should stimulate and support the defense statu s of this patien t by eliminating the pathogen at sites where antibiotics were not effective (e.g., skin abscesses).
Moreover, antibiotic therapy alone, in the absence of host defense mechanisms, often appears to be unable to cure infections, espec ially those with intracellular pathogens (authors' unpublished observations) . Further, a previous study [2] reported the beneficial effect of combination therapy with imipenem and plasma for chronic campylobacter infections.
Before the initiation of the new treatment, in vitro studies were performed to investigate whether the patient's PMNLs were principally able to kill the pathogen at least under experimental conditions and which immunologic compound might be effective as immunomodulating treatment. To evaluate the bacteri cidal activity of the patient' s PMNLs against Campy lobacter, CL responses of PMNLs were assayed in the presence of various Ig preparations and sera . The patient's PMNLs showed only weak CL responses when they were expo sed to viable Cijejuni in the patient' s serum or commercial Ig preparation s (figure 3). Experiments with heat-killed C.jej uni revealed comparable results (data not shown).
In agreement with recently publi shed results [10] , only IgMcontaining preparations (Pentaglobin) enhanced the bactericidal effects ofPMNLs against Campylobacter (P < .05). However, the strongest responses to CL were observed when PMNLs
Results and Discussion
Duplicates of serial dilutions of these suspensions were plated on meat-yeast extract agar, and cfu were counted after incubation for 48 hours at 42°C.
Statistical analysis. Differences between mean values were analyzed by the Student's t test. P values of < .05 were considered statistically significant. was poor because of the chronic persistent C. jejuni infection, we decided to start combination therapy with maternal plasma and ciprofloxacin to rapidly clear the pathogen.
To study the effect of transferring maternal plasma to the patient, blood was sampled at various intervals after transfusion, and Luminol-treated PMNLs were assayed for CL. The results showed that immediately after transfusion the patient's serum enhanced CL responses >30% when PMNLs were exposed to C. jejuni (P < .05; data not shown). These results suggest that transfer of maternal plasma to the patient might have enhanced the bactericidal activity of the patient's PMNLs against Campy/obacter in vivo.
PMNL mother mother patient patient Serum mother patient mother patient Ig prep. CID 1996;23 (September) Therapy with ciprofloxacin (250 mg orally twice a day) was continued for another 20 days. Five days after the therapy was started, C. jejuni could no longer be detected in blood, skin, and stool specimens, thus suggesting that the combination therapy cured the C.jejuni infection in this patient. FolIow-up for a further 12 months confirmed that the chronic refractory C. jejuni infection in this patient was cured with combination treatment with maternal plasma and ciprofloxacin.
However, we do not yet know which component of maternal plasma mediated the observed immunobiological effects. Surprisingly, we detected only insignificant low levels of C. jejuni-specific antibody in maternal serum by means of immunoblotting (data not shown). Moreover, it is not yet known whether inhibitory components were present in the patient's serum as suggested by the data presented in figures 3 and 4. Thus, systemic studies are required to elucidate the therapeutic effect of maternal plasma. On the other hand, we cannot exclude the possibility that ciprofloxacin therapy alone might have caused eradication of the pathogen.
It is interesting that T cell responses specific for C. jejuni in our patient were very weak (P < .05) only when they were compared with those in a patient with acute C.jejuni infection, while T cell responses upon exposure to a recalI antigen (tetanus toxoid) in our patient were pronounced compared with those in controls (table 1) . Whether these findings are because of a so far unknown T celI deficiency in the patient, a T celI tolerance due to persistent infection, or a deficiency in antigen presentation as a result of the lack of phagocytosis of C.jejuni in vivo is not yet clear. However, although the role ofT cells in the host response to C.jejuni infection has yet to be established, recent data from models of infection with other enteroinvasive, extracellular bacteria (such as Y. enterocolitica) argue for such a role [15, 16] . Finally, the strain isolated from our patient did not hydrolyze hippurate but was identified as C. jejuni by 16S rRNA gene sequencing. Although >99% of C.jejuni strains do hydrolyze [17] recommend that hippurate hydrolysis [18] should not be used as a sole criterion for differentiation between these Campylobacter species.
